Published in Medical Verdicts and Law Weekly, July 27th, 2006
"The product development and manufacturing agreement with Progenitor Cell Therapy is a critical component of our corporate and product development plan," explained Thomas Moss, Amorcyte's chief medical officer. "Our strategic relationship with PCT enables our development team to draw on PCT's unique and extensive investigative,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.